Public Sector Pension Investment Board Acquires 788 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Public Sector Pension Investment Board grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.4% during the 3rd quarter, HoldingsChannel reports. The fund owned 8,379 shares of the biopharmaceutical company’s stock after buying an additional 788 shares during the period. Public Sector Pension Investment Board’s holdings in Regeneron Pharmaceuticals were worth $4,711,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in the stock. Ground Swell Capital LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth about $574,000. Illinois Municipal Retirement Fund increased its position in shares of Regeneron Pharmaceuticals by 11.0% during the third quarter. Illinois Municipal Retirement Fund now owns 26,287 shares of the biopharmaceutical company’s stock valued at $14,780,000 after buying an additional 2,599 shares during the period. Varma Mutual Pension Insurance Co lifted its holdings in shares of Regeneron Pharmaceuticals by 9.3% in the third quarter. Varma Mutual Pension Insurance Co now owns 19,888 shares of the biopharmaceutical company’s stock worth $11,182,000 after buying an additional 1,700 shares in the last quarter. Sound Shore Management Inc CT bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $64,677,000. Finally, Leuthold Group LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $3,398,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Cantor Fitzgerald upped their target price on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Finally, Wells Fargo & Company boosted their price objective on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $793.81.

Insider Transactions at Regeneron Pharmaceuticals

In other news, SVP Jason Pitofsky sold 2,036 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the sale, the senior vice president owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. This represents a 32.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the transaction, the director directly owned 17,803 shares in the company, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 3,636 shares of company stock worth $2,862,920. 7.02% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Trading Down 1.2%

Shares of REGN stock opened at $782.38 on Friday. The business has a 50-day moving average price of $768.21 and a two-hundred day moving average price of $671.68. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The firm has a market cap of $82.71 billion, a P/E ratio of 18.83, a price-to-earnings-growth ratio of 2.13 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the company earned $12.07 EPS. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend is Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 8.47%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.